<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8555765</PMID><DateCompleted><Year>1996</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0037-9085</ISSN><JournalIssue CitedMedium="Print"><Volume>88</Volume><Issue>3</Issue><PubDate><Year>1995</Year></PubDate></JournalIssue><Title>Bulletin de la Societe de pathologie exotique (1990)</Title><ISOAbbreviation>Bull Soc Pathol Exot</ISOAbbreviation></Journal><ArticleTitle>[Post-vaccination anti-poliomyelitis seroprevalence in an urban setting in Abidjan].</ArticleTitle><Pagination><StartPage>117</StartPage><EndPage>120</EndPage><MedlinePgn>117-20</MedlinePgn></Pagination><Abstract><AbstractText>In order to determine the antipoliomyelitis seroprevalence of children in Abidjan, we checked the presence of antipoliovirus antibodies in 48 children received in the South Abobo's vaccination center for vaccination against measles. According to the vaccination schedule and rules applied in C&#xf4;te d'Ivoire: 12.5% of the children have received less than three doses or oral polio vaccine (OPV), 87.5% have received the three doses. Antibody titration results indicated that 78.6, 93 and 76.2% of the children have been immunized against Poliovirus type I, type II and type III, respectively; 71.4% of the children showed antibodies against the three poliovirus serotypes and 4.8% had no antipoliovirus antibodies at all. The children which showed an antibodies titer less than 1/8 were considered unprotected: the proportion of unprotected was 21.4, 7 and 23.8% against Poliovirus type I, type II and type III, respectively. Although these results showed that the level of protection against poliomyelitis in Abidjan is acceptable (&gt; 75%), the efforts for vaccination program in C&#xf4;te d'Ivoire need to be improved in order to eradicate poliomyelitis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akoua-Koffi</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institut Pasteur de C&#xf4;te d'Ivoire.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thonnon</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kouassi-Renaud</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Dosso</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ehouman</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>S&#xe9;ropr&#xe9;valence antipoliomy&#xe9;litique post-vaccinale en milieu urbain &#xe0; Abidjan.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Bull Soc Pathol Exot</MedlineTA><NlmUniqueID>9212564</NlmUniqueID><ISSNLinking>0037-9085</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001500">BCG Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015721">Diphtheria-Tetanus-Pertussis Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008458">Measles Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001500" MajorTopicYN="N">BCG Vaccine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007560" MajorTopicYN="N" Type="Geographic">Cote d'Ivoire</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015721" MajorTopicYN="N">Diphtheria-Tetanus-Pertussis Vaccine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008458" MajorTopicYN="N">Measles Vaccine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014504" MajorTopicYN="Y">Urban Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8555765</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>